Associate Professor Jason Grebely and Dr Ki Wook Kim – SPHERE 2017 seed grant showcase - Annual reports

Event type: 
Event date: 
Tuesday, 11 September 2018 - 1:00pm to 2:00pm
Berg Family Foundation Seminar Room, Level 6, Wallace Wurth Building, Kensington Campus, UNSW Sydney
Contact for inquiries: 
Rata Joseph, +61 (2) 9385 0900 or
Booking deadline: 

Kirby Institute Seminar Series presents

Associate Professor Jason Grebely

Associate Professor Jason Grebely

Senior Research Fellow, Kirby Institute, UNSW Sydney

Associate Professor Jason Grebely’s research focuses on the epidemiology and treatment of hepatitis C, with a focus on people who inject drugs. He is also the President of the International Network on Hepatitis in Substance Users, an international body for improving knowledge translation, education and advocacy for HCV among people who inject drugs.

Twitter: @jasongrebely

image - Associate Professor Jason Grebely and Dr Ki Wook Kim – SPHERE 2017 seed grant showcase - Annual reports
Dr Ki Wook Kim

Dr Ki Wook Kim

Postdoctoral Research Scientist, School of Women's and Children's Health, UNSW Sydney

Dr Ki Wook Kim is an Early-career Postdoctoral Scientist at the School of Women’s and Children’s Health at the University of New South Wales, based within the Prince of Wales Hospital. He completed Bachelors, Honours and PhD at the University of Sydney specialising in Molecular Biology and Genetics.


Enhancing hepatitis C testing and treatment among people who inject drugs in needle and syringe programs: the TEMPO Study
Associate Professor Jason Grebely

Despite advances in hepatitis C treatment, efforts are urgently needed to enhance testing to strive towards hepatitis C elimination. This presentation will summarise the SPHERE-funded TEMPO Project, which aims to evaluate the impact of an intervention to enhance hepatitis C testing and treatment in needle and syringe program services.

Detection of viruses that promote islet autoimmunity and type 1 diabetes using VirCapSeq and Peptide arrays
Dr Ki Wook Kim

Viruses have long been studied as candidate triggers of islet autoimmunity, which precedes the development of type 1 diabetes in most cases. However, the selective focus on a small number of candidate viruses using targeted detection methods increases risk of substantial investigation bias. To alleviate this, we are using the most sensitive, unbiased and comprehensive tools available to characterise changes in the gut and blood virome that precede the development of islet autoimmunity and type 1 diabetes. Our data will inform the development of vaccines to prevent type 1 diabetes.